Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier

References

• Younunossi ZH, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver Diseases in USA in the past three decades. Gut. 2020;69:203–209.
   Web of Science ®Google Scholar
• Escorcia Charriz EJ, et al. INEGI Comunicado de prensa núm 592/21. Bioc. 2018;13:17–30.
   Google Scholar
• Huang DQ, Tarrault NA, Tacke F, et al. Global epidemiology of cirrhosis- aetiology, trends and predictions. Nature Rev Gastroenterol Hepatol. 2023;28:1–11. doi:10.1038/s41575-023-00750-2
   Google Scholar
• Yeo YH, He X, Lu F, et al. Trends of cirrhosis-related mortality in USA during the COVID-19 pandemic. J Clin Transl Hepatol. 2023;11(3):751–756. doi:10.14218/JCTH.2022.00313
   PubMed Web of Science ®Google Scholar
• Prabhakar T, Kaushal K, Prasad H, et al. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: s multicentric study. Hepatol Int. 2023. doi:10.1007/s12072-023-10498-16
   PubMed Web of Science ®Google Scholar
• D’Amico G, García-Tsao G, Pagliaoro L. Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. doi:10.1016/j.jhep.2005.10.013
   PubMed Web of Science ®Google Scholar
• Zubieta-Rodríguez R, Gómez-Correa J, Rodríguez-Amaya R, et al. Mortalidad hospitalaria en pacientes cirróticos en un hospital de tercer nivel. Rev Gastroenterol Mx. 2017;82:203–209.
   PubMedGoogle Scholar
• Rabiee A, Mahmud N, Falker C, et al. Medication for alcohol use disorder improve survival in patients with hazardous drinking and alcohol associated cirrhosis. Hepatol Commun. 2023;7(4):20093. doi:10.1097/HC9.0000000000000093.eCollection
   Web of Science ®Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Int Med. 2013;158(5_Part_1):329–337. doi:10.7326/0003-4819-158-5-201303050-00005
   PubMed Web of Science ®Google Scholar
• Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, et al. Consenso mexicano para el tratamiento de la hepatitis C. Rev Mex Gastroenterol. 2018;83:295–324.
   Google Scholar
• Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive intervention program on portal hypertension in patients with cirrhosis and obesity. The SportDiet study. Hepatology. 2017;65(84):1293–1305. doi:10.1002/hep.28992
   PubMedGoogle Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotheraphy. 2005;51(Suppl 1):36–66.
   PubMed Web of Science ®Google Scholar
• Viscomi GC, Campana M, Barbanti M, et al. Crystal form of rifaximin and their effect on pharmaceutical properties. Cryst Eng Comm. 2008;10(8):1074–1108. doi:10.1039/b717887e
   Google Scholar
• Ojetti V, Lauritano EC, Barbaro F, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009;5(6):675–682. doi:10.1517/17425250902973695
   PubMed Web of Science ®Google Scholar
• Novoa-Farías O, Frati-Munari AC, Peredo MA, et al. Susceptibility of bacteria isolated from acute gastrointestinal infections to rifaximin and other antimicrobial agents in Mexico. Rev Gastroenterol Mex. 2016;81(1):3–10. doi:10.1016/j.rgmx.2015.07.003
   PubMedGoogle Scholar
• Novoa-Farias O, Frati-Munari AC, Peredo MA, et al. Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico. Rev Gastroenterol Mex. 2017;82(3):226–233. doi:10.1016/j.rgmx.2016.10.006
   PubMedGoogle Scholar
• Solórzano-Santos F, Piña-Flores LI, Priego-Hernández G, et al. Actividad antibacteriana de la rifaximina y otros siete antibióticos contra las bacterias enteropatógenas aisladas de niños con diarrea aguda. Rev Mex Pediat. 2018;85:45–52.
   Google Scholar
• Calanni F, Renzulli C, Barbanti M, Viacomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot. 2014;67(9):667–670. doi:10.1038/ja.2014.106
   PubMed Web of Science ®Google Scholar
• Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14(3):290–295. doi:10.1179/joc.2002.14.3.290
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65(12):2556–2565. doi:10.1093/jac/dkq345
   PubMed Web of Science ®Google Scholar
• Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309–325. doi:10.2147/CEG.S89999
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Scaldaferri F, Petito V, et al. The Role of Antibiotics in Gut Microbiota Modulation: the Eubiotic Effects of Rifaximin. Dig Dis. 2016;34(3):269–278)SE. doi:10.1159/000443361
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with Rifaximin modulates lamina propia monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):246–256. doi:10.1159/000068362
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gilliland M, et al. Rifaximin alters intestinal bacteria and prevent stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484–496. doi:10.1053/j.gastro.2013.10.026
   PubMed Web of Science ®Google Scholar
• Jin Y, Ren X, Li G, et al. Rifaximin exerts beneficial effects in PI-IBS mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443–452. doi:10.1111/jgh.13841
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol. 2010;80(11):1700–1707. doi:10.1016/j.bcp.2010.08.022
   PubMed Web of Science ®Google Scholar
• Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Ex Ther. 2010;335(1):32–41. doi:10.1124/jpet.110.170225
   PubMed Web of Science ®Google Scholar
• Patel VC, Shawcross DL, McPhail MJL Scientific report: a placebo controlled single center double blind randomized trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004708-20/results. Accessed October 17, 2023.
   Google Scholar
• Cheng J, Ze-Fang Z, Nagaoka K, et al. Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium induce colon cancer. J Pharmacol Exper Ther. 2014;351(3):559–567. doi:10.1124/jpet.114.215913
   PubMed Web of Science ®Google Scholar
• Xie C, Singal AK. Rifaximin-α in alcohol-associated liver disease. Lancet Gastroenterol Hepatol. 2023;8(6):495–497. doi:10.1016/s2468-1253(23)00033-x)
   PubMed Web of Science ®Google Scholar
• Israelsen M, Madsen BS, Torp N, et al. Rifaximin-αfor liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomized. Double-blind, placebo-controlled, phase-2 trial. Lancet Gastroenterol/Hepatol. 2023. doi:10.1016/s2468-1253(23)00010-9
   Google Scholar
• Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, et al. Consenso mexicano de la enfermedad por hígado graso no alcohólico. Rev Gastroenterol Mex. 2019;84:69–99.
   PubMed Web of Science ®Google Scholar
• Escorcia Charris EJ, Marrugo-Balcero WR. Caracterización biológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica General del Norte. Enero 2012 a marzo 2017. Biociencias. 2018;13(1):17–30. doi:10.18041/2390-0512/bioc.1.2242
   Google Scholar
• Oseinim AM, Sanjal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(suppl 1):97–103. doi:10.1111/liv.13302
   PubMedGoogle Scholar
• Perumpail BJ, Li AA, John V, et al. The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD. Diseases. 2019;7(27):1–12. doi:10.3390/diseases7010027
   Google Scholar
• Cobbold JFL, Atkinson S, Marchesi JR, et al. Rifaximin in non-alcoholic steatohepatitis: an open-label pilot study. Hepatol Res. 2018;48(1):60–77. doi:10.1111/hepr.12904
   Web of Science ®Google Scholar
• Gangarapu V, Ince AT, Baysal B, et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27(7):840–845. doi:10.1097/MEG.0000000000000348
   PubMed Web of Science ®Google Scholar
• Abdel-Razik A, Mousa N, Shebana W, et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30(10):1237–1246. doi:10.1097/MEG.0000000000001232
   PubMed Web of Science ®Google Scholar
• Fujinaga Y, Kawaratani KI, Kawa D, et al. Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(15):5589. doi:10.3390/ijms21155589
   PubMed Web of Science ®Google Scholar
• Enomoto M, Kaji K, Nishimura N, et al. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis. 2022;54(10):1392–1402. doi:10.1016/jdid2022.04.012
   PubMedGoogle Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450–455. doi:10.1111/jgh.12070
   PubMed Web of Science ®Google Scholar
• Jian J, Nie MT, Xiang B, et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids. Front Pharmacol. 2022;13. doi:10.3389/fpharm2022.841132
   Web of Science ®Google Scholar
• Eriksen PL, Djernes L, Vilstrup H, Ott P. Clearance and production of ammonia quantified in humans by constant ammonia infusion- The effect of cirrhosis and ammonia targeting treatments. J Hepatol. 2023;s0168-8278:220.
   Google Scholar
• Won SM, Oh KK, Gupta H. The link between gut microbiota and hepatic encephalopathy. Int J Mol Sci. 2022;21(16):8999. doi:10.3390/ijms23168999
   Google Scholar
• Yu X, Jin Y, Zhou W, et al. Rifaximin moderates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistant. Front Cell Infect Microbiol. 2022.
   Web of Science ®Google Scholar
• Yukawa-Muto Y, Kamlya T, Fujii H, et al. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. Hepatol Comm. 2022;1:1–15.
   Google Scholar
• Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLOSone. 2022;17:e8267647. doi:10.1371/journal.pone.0267647
   Web of Science ®Google Scholar
• Chang C, Huang CH, Tseng H, et al. Real-world experience of one-year efficacy of rifaximin add-on to lactulose is superior to lactulose alone in patients with cirrhosis complicated with recurrent hepatic encephalopathy in Taiwan. J Pers Med. 2021;11:478. doi:10.3390/jpm11060478
   PubMed Web of Science ®Google Scholar
• Volk ML, Burne R, Guerin A, et al. Hospitalizations and health care costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. J Med Econ Doi. 2021;24:202.
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Tawaki N, Nakanishi H, et al. Add-on therapeutic effects of rifaximin on treatment – resistant hepatic encephalopathy. Internal Med. 2022. doi:10.2169/internalmedicine0212
   Web of Science ®Google Scholar
• Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174(5):533–640. doi:10.7326/M20-0202
   PubMed Web of Science ®Google Scholar
• Garring J, Müller L, Kloeckner R, et al. Review article: post- TIPSS hepatic encephalopathy—current knowledge and future perspectives. Aliment Pharmacol Ther. 2022;55(10):1265–1276.
   PubMed Web of Science ®Google Scholar
• Nakai N, Suda G, Ogawa K, et al. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. PLoS One. 2022;17(7):20270786. doi:10.1371/journal.pone.0270786
   Web of Science ®Google Scholar
• Ballester MP, Gallego JJ, Fiorillo A, et al. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Scientific Rep. 2022;12(1):2463. doi:10.1038/s41598-022-06416-z
   PubMed Web of Science ®Google Scholar
• Tau W, Wang J, Shi PM, et al. Effect of low-dose and high-dose rifaximin in the treatment of covert hepatic encephalopathy. J Clin Transl Hepatol. 2022;10(6):1099–1106. doi:10.14218/JCTH.2021.00457
   PubMed Web of Science ®Google Scholar
• De Jong LA, van Schoonhoven AV, Hofstra HS, et al. Budget impact of optimizing rifaximin-α use for prevention of recurrent hepatic encephalopathy in the Netherlands. J Med Econ. 2021;24(1):1149–1163. doi:10.1080/13696998.2021.1983291
   PubMed Web of Science ®Google Scholar
• Frati-Munari AC, Galindo-Sanchez RM. Rifaximina-α en la encefalopatía hepática. Consideraciones farmacoeconómicas para México. Med Int Mex. 2020;31:621–663.
   Google Scholar
• Stoll AM, Guido M, Pence A, Gentene AJ. Lack of access to rifaximin upon hospital discharge is frequent and results in increased hospitalizations for hepatic encephalopathy. Ann Pharmacoither. 2022. doi:10.1177/10600280221100537)
   Google Scholar
• De Graeve J, Vanderstracten E, Dlvaeye T, et al. The impact of rifaximin in the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study. Acta Gastroenterol Belg. 2022;85(1):1–5. doi:10.51821/85.1.9365
   PubMedGoogle Scholar
• Praharaj DL, Premikuwar H, Roy A, et al. Rifaximin Vs norfloxacin for spontaneous bacterial peritonitis prophylaxis: a randomized controlled trial. J Clin Exper Hepatol. 2022;12(2):336–342. doi:10.1016/j.jceh.2021.08.010
   PubMed Web of Science ®Google Scholar
• Pimentel R, Gregorio C, Figuereido V. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis: a systematic review. Acta Gastroenterool Belg. 2021;84(2):333–341. doi:10.51821/84.2.333
   PubMed Web of Science ®Google Scholar
• Faust N, Yamada A, Haider H, et al. Systematic review and network meta-analysis. Prophylactic antibiotic therapy for spontaneous bacterial peritonitis. World J Hepatol. 2020;18(5):239–252. doi:10.4254/wjh.v12.i5.239
   Google Scholar
• Lu XY, Ding HG, Zheng JF, et al. Rifaximin improves survival in cirrhotic patients with refractory ascites: a real world study. World J Gastroenterol. 2020;26(2):199–218. doi:10.3748/wjg.v26.i2.199
   PubMed Web of Science ®Google Scholar
• Yokohama K, Fukuda J, Yamauchi R, et al. Long-term effects of rifaximin on patients with hepatic encephalopathy: its possible effects on the improvement in the blood ammonia concentration levels, hepatic spare ability and refractory ascites. Medicine. 2022;58:1276.
   Google Scholar
• Zubieta-Rodeíguez S, Gómez-Correa J, Rodríguez-Amaya R, et al. Mortalidad hospitalaria en pacientes cirróticos en un hospital de tercer nivel. Rev Gastroenterol Mex. 2017;82(3):203–209. doi:10.1016/j.rgmx.2016.10.002
   PubMedGoogle Scholar
• Higuera-De la Tijera F, Soto-Martinez K, Funez-Madrid VM, et al. Long-term rifaximin is safe and its related to less frequency of complications like variceal bleeding in cirrhotic patients. Ann Hepatol. 2021;24:100366. doi:10.1016/j.aohep.2021.100518
   Google Scholar
• Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Ther Adv Gastroenterol. 2018;11:1–10. doi:10.1177/1756284818800307
   Web of Science ®Google Scholar
• Zeng X, Sheng X, Wang PQ, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated cirrhosis. Hepatol Int. 2021;15(1):155–165. doi:10.1007/s12072-020-10117-y)
   PubMed Web of Science ®Google Scholar
• Lee S, Saffo S. Evolution of care in cirrhosis. Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterl. 2023;29(1):61–74. doi:10.3748/wjg.v29.i1.61
   PubMed Web of Science ®Google Scholar
• Patel AH, Li Y, Minacapoll CD, et al. Reduction in gastrointestinal cancers in cirrhotic patients receiving rifaximin vs lactulose only therapy for hepatic encephalopathy. Cureus. 2023;15(2):e35259. doi:10.7759/cureus.35259
   PubMed Web of Science ®Google Scholar
• D´Amico M, Pasta L, Malizia G, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563–576. doi:10.1016/j.jhep.2017.10.020
   PubMed Web of Science ®Google Scholar
• Tandon P, Ismond KP, Riess K, et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol. 2018;69: (5(5):1164–1177. doi:10.1016/j.jhep.2018.06.017
   Web of Science ®Google Scholar
• Degré D, Stauber RE, Englebert G, et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32. J Hepatol. 2020;72(4):636–642. doi:10.1016/j.jhep.2019.12.023
   PubMed Web of Science ®Google Scholar
• El Sherif O, Dhaliwai A, Newsome PN, et al. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14(3):197–205. doi:10.1080/17474124.2020.1731303
   PubMed Web of Science ®Google Scholar
• Lens S, Baiges A, Alvarado Tapias E, et al. Clinical outcome and hemodynamics changes following HCV eradication with oral antiviral therapy in patients with clinical significant portal hypertension. J Hepatol. 2020;73(6):1415–1424. doi:10.1016/j.jhep.2020.05.050
   PubMed Web of Science ®Google Scholar
• Bajaj JS. Potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43(Suppl1):11–26. doi:10.1111/apt.13435
   PubMedGoogle Scholar
• Lv X-Y, Ding H-G, Zheng J-F, Fan C-L, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: a real world study. World J Gastroenterol. 2020;26(2):199–218.
   PubMed Web of Science ®Google Scholar
• Flamm SL, Mullen KD, Heimanson Z. Rifaximin has the potential to prevent complications of cirrhosis. Ther Adv Gastroenterol. 2018;11:1756284818800307.
   Web of Science ®Google Scholar
• Dong T, Aronsohn A, Gautham Reddy K, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 2016;61(12):3621–3626. doi:10.1007/s10620-016-4313-0
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Hassanenn AM. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short term survival. Eur J Gastroenterol Hepatol. 2016;28(12):1455–1461. doi:10.1097/MEG.0000000000000743
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Giochetti P. Rifaximin-EIR (Extended Intestinal Release) 400 mg tablets (investigator´s brochure) Covington, LA. Alfasigma. Gut. 2016:59.
   PubMedGoogle Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390–1397 e.2−. doi:10.1016/j.cgh.2013.12.021
   PubMed Web of Science ®Google Scholar